BACKGROUND: A recent revision in thyroid tumor nomenclature has resulted in a change from a malignant diagnosis (noninvasive follicular variant of papillary thyroid carcinoma) to one that is nonmalignant (noninvasive follicular thyroid neoplasm with papillary-like nuclear features [NIFTP]). The objective of the current study was to evaluate the impact of this change on the performance of the Afirma gene expression classifier (GEC). METHODS: The authors retrospectively analyzed consecutive thyroid fine-needle aspiration specimens with indeterminate diagnoses on which GEC was performed. Surgical pathology material was reviewed with the reclassification of nodules into NIFTP. RESULTS: GEC testing was performed on 384 fine-needle aspiration specimens diagnosed as atypia of undetermined significance (AUS) (304 cases) and suspicious for a follicular neoplasm (SFN) (80 cases) and yielded a suspicious result in 152 of the AUS cases (50%) and 50 of the SFN cases (63%). Thyroidectomy was performed on 177 patients. After reclassifying NIFTP, the positive predictive value of GEC decreased from 42% (95% confidence interval [95% CI], 39%-45%) to 24% (95% CI, 22%-26%) in the AUS group and from 23% (95% CI, 19%-27%) to 13% (95% CI, 9%-18%) in the SFN group. Total thyroidectomy was performed more frequently than a partial thyroidectomy in patients with AUS with a suspicious GEC result compared with pre-GEC controls (68% vs 49%; P 5.037). CONCLUSIONS: Reclassification of NIFTP significantly decreases the positive predictive value of GEC in indeterminate thyroid nodules. Nevertheless, the majority of patients with indeterminate thyroid nodules with a suspicious GEC result in the study institution have undergone total thyroidectomy. This finding raises concerns over reliance on a suspicious GEC result by clinicians to justify total thyroidectomy. Cancer Cytopathol 2017;125:683-91.
INTRODUCTION
The thyroid nodule is a common clinical problem. Palpable thyroid nodules have been reported in approximately 6% of women and 1% of men in the general population of iodine-sufficient regions. 1 The reported prevalence is even higher with the use of ultrasonography, demonstrating a range from 20% to 70% depending on patient age and sex. 2, 3 Although clinically detectable thyroid nodules raise a concern of cancer, only 5% to 15% of these nodules are found to be malignant. 4, 5 Given the high prevalence and the low rate of malignancy, fine-needle aspiration (FNA) plays an important role in evaluating thyroid nodules. Since 2010, The Bethesda System for Reporting Thyroid Cytopathology has established standardized criteria for reporting thyroid FNA results in 6 diagnostic categories with an estimated risk of malignancy and recommended clinical management for each. 6 FNA is able to classify 60% to 85% of thyroid nodules as benign, which exempts these patients from unnecessary surgery. 7 Conversely, the indeterminate categories, which include atypia of undetermined significance (AUS) and suspicious for a follicular neoplasm (SFN), comprise 10% to 26% of all thyroid FNAs, and remain heterogeneous in cancer prediction. These indeterminate FNA diagnoses are associated with malignancy rates of 14% to 48% and cause dilemmas in clinical decision making. 7, 8 Molecular testing has emerged as an increasingly useful ancillary tool with which to stratify patients with indeterminate thyroid FNA nodules for diagnostic surgery. 9, 10 To the best of our knowledge, the Afirma gene expression classifier (GEC) (Veracyte Inc, South San Francisco, Calif) is one of the most widely used commercial tests in the United States. In the validation study, there were 129 patients with AUS nodules and 81 patients with SFN nodules who underwent surgery and histopathologic confirmation. 11 The results demonstrated that GEC had a high negative predictive value (NPV) of 95% in the AUS group and 94% in the SFN group. The risk of malignancy of indeterminate thyroid nodules with a benign GEC result was comparable to that of a nodule with a cytologically benign FNA. This supports using GEC as a "rule-out" test, and that patients with indeterminate nodules with a benign GEC result should be managed conservatively. Conversely, given a lower than expected positive predictive value (PPV) of 38% in the AUS group and 37% in the SFN group, a suspicious GEC result is less helpful in clinical decision making. In the past 20 years, the incidence of the follicular variant of papillary thyroid carcinoma (FVPTC) has increased by 2-fold to 3-fold. It has become the most common variant of papillary thyroid carcinoma (PTC) diagnosed in North America and Europe. 12, 13 Recent studies have shown that noninvasive FVPTC has a very indolent clinical behavior in contrast to infiltrative FVPTC, [14] [15] [16] [17] [18] and is genetically distinct with a higher frequency of RAS mutations and an absence of BRAF mutations. 15, 17, 19 Given the indolent behavior of the noninvasive tumor, a panel of experts has lately introduced a new terminology, "noninvasive follicular thyroid neoplasm with papillarylike nuclear features (NIFTP)," with a consensus on diagnostic criteria to avoid classifying this low-grade tumor as carcinoma. 20 The initial prospective validation of GEC did not consider noninvasive FVPTC, 11 and to our knowledge the impact of the novel concept of NIFTP on the performance of GEC has only been evaluated in 3 recent studies with a smaller sample size. [21] [22] [23] In the current study, we retrospectively examined the distribution of GEC results in histologically confirmed cases of NIFTP, evaluated the changes to the overall performance of the test, and assessed the potential influence on clinical management.
MATERIALS AND METHODS

Case Selection
The current study was approved by the Institutional 20 which included: 1) encapsulation or clear demarcation from nonneoplastic thyroid parenchyma; 2) a nearly entirely follicular growth pattern; and 3) nuclear features of PTC. The exclusion criteria included: 1) true papillae > 1%; 2) the presence of psammoma bodies; 3) infiltrative border; 4) tumor necrosis; 5) high mitotic activity; or 6) morphologic features of other variants of PTC. Cases without initial agreement were resolved by consensus on a multihead microscope. Whether subcentimeter nodules could be classified as NIFTP was still controversial because these nodules were excluded from the consensus study. 20 However, we believe these cases should still have an indolent behavior as NIFTP, and that it is reasonable to make this distinction from the original FVPTC diagnosis.
Pooled Performance Analysis
A search in PubMed for literature regarding the Afirma GEC and indeterminate thyroid nodules in the period before December 31, 2016 was performed. The inclusion criteria included: 1) studies of AUS and SFN (including suspicious for Hurthle cell neoplasm) with GEC test results and histopathologic confirmation; and 2) studies providing detailed results (number of true-positive, false-positive, true-negative, and false-negative findings) in individual categories. A pooled performance analysis was performed using data from the studies reviewed.
Statistical Analysis
Data were summarized using descriptive statistics (mean and range for continuous variables and count and frequency for categorical variables). Student t tests were performed to test the null hypothesis that the mean values of continuous variables are identical between 2 cohorts. Fisher exact tests were performed to compare proportions of categorical variables between 2 cohorts, except in size groups of thyroid nodules, for which Pearson's chi-squared tests were applied. Sensitivity, specificity, PPVs, and NPVs of GEC results in identifying malignancy before and after reclassification of NIFTP were examined for cases among patients who underwent thyroidectomy and histopathologic examination. Binomial proportion confidence intervals (CIs) containing the true proportion 95% of the time were reported. Two-sided P values < .05 were considered to be statistically significant. Statistical analyses were performed using R statistical software (version 3.2.2; R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Characteristics of the Study Cohort
A total of 375 patients with 384 indeterminate nodules (304 with an AUS diagnosis and 80 with an SFN diagnosis) who had undergone GEC testing were identified. There were 104 men and 271 women with a mean age of 54 years (range, 8-90 years). The demographics, size of the thyroid nodules, and surgical procedures based on FNA diagnoses and GEC results are summarized in Table  1 . Five patients had 2 nodules with an AUS diagnosis, 1 patient had 2 nodules with an SFN diagnosis, and 3 patients had nodules with an AUS and SFN diagnosis in each. In the AUS group, 152 nodules (50%) demonstrated a suspicious GEC result, 141 nodules (46%) demonstrated a benign GEC result, and 11 nodules (4%) showed no GEC result due to an insufficient RNA yield. 
Corresponding Histopathologic Diagnoses
The corresponding histopathologic diagnoses of the patients with indeterminate thyroid nodules that had Impact of NIFTP on Afirma GEC/Hang et al
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undergone GEC testing are summarized in Table 2 . The rate of malignancy in nodules found to be suspicious on GEC from the AUS group and the SFN group was 42% and 23%, respectively. The rate of neoplasia in nodules found to be suspicious on GEC from the AUS group and the SFN group was 67% and 64%, respectively. FVPTC comprised the majority of malignant tumors with an indeterminate FNA diagnosis (62% in the AUS group and 56% in the SFN group). One patient with FVPTC diagnosed in the SFN group had a benign GEC result. No malignant tumor in the AUS group was found to have a benign GEC result. All Hurthle cell neoplasms except one case of a Hurthle cell adenoma had a suspicious GEC result.
Review and Reclassification of FVPTC as NIFTP
All 37 FVPTC cases underwent histopathologic review. Using the revised nomenclature recognizing NIFTP, the cases were reclassified as NIFTP (25 cases; 68%) and invasive FVPTC (9 cases; 24%, including the case with a benign GEC result). Three cases without initial agreement were diagnosed by consensus using a multihead microscope as noninvasive FVPTC with solid growth (1 case; 3%), classic PTC (1 case; 3%), and follicular adenoma with reactive changes (1 case; 3%). All NIFTP cases were submitted in their entirety except for 1 tumor measuring 4.8 cm, for which the entire capsule was submitted. Four ( Original Article tumors reclassified as NIFTP measured <1 cm (range, 0.6-0.8 cm). For the NIFTP cases, 19 had been diagnosed as AUS with a suspicious GEC result, 2 had been diagnosed as AUS with no GEC result due to an insufficient RNA yield, and 4 cases had been diagnosed as SFN with a suspicious GEC result. Reclassification using the NIFTP nomenclature significantly changed the prevalence of malignancy in the AUS group from 35% to 20% (P 5 .009).
Performance of GEC Before and After NIFTP Reclassification
The performance of GEC in identifying malignancy before and after reclassification is summarized in Table 3 . In the AUS group, although the NPV of malignancy remained excellent, the PPV of malignancy decreased significantly from 42% (95% CI, 39%-45%) to 24% (95% CI, 22%-26%). In the SFN group, the PPV also decreased significantly from 23% (95% CI, 19%-27%) to 13% (95% CI, 9%-18%). However, the number of benign GEC cases with surgery was too few (3 cases) to confidently assess the NPV.
Comparison of Surgical Procedure With Pre-GEC Controls
After excluding cases with bilateral nodules at the time of initial presentation (15 patients in the AUS group and 4 patients in the SFN group), we compared the surgical procedure (total thyroidectomy vs partial thyroidectomy) in patients with an indeterminate thyroid nodule determined to be suspicious on GEC with pre-GEC controls. The result demonstrated a significantly higher rate of total thyroidectomy in the AUS group with a suspicious GEC result compared with pre-GEC controls 
Pooled Performance Analysis
Eight studies including the current study fulfilled the inclusion criteria for the pooled analysis; the result is summarized in Table 4 . 11, [24] [25] [26] [27] [28] [29] Because none of the studies regarding the Afirma GEC and NIFTP provided detailed information, all the data were obtained from studies conducted without the consideration of NIFTP. The prevalence of malignancy was 34% (95% CI, 30%-39%) in the pooled AUS group and 32% (95% CI, 26%-38%) in the pooled SFN group. The pooled performance analysis demonstrated a sensitivity, specificity, PPV, and NPV of 98% (95% CI, 94%-100%), 31% (95% CI, 26%-37%), 42% (95% CI, 40%-45%), and 97% (95% CI, 90%-99%), respectively, for AUS; and 94% (95% CI, 87%-98%), 25% (95% CI, 19%-32%), 37% (95% CI, 34%-39%), and 90% (95% CI, 78%-96%), respectively, for SFN. The rate of neoplasia in GEC-suspicious nodules was 69% in the pooled AUS group and 79% in the pooled SFN group.
DISCUSSION
Since its introduction into the clinical arena in 2011, the GEC test has been used increasingly as an ancillary tool with which to stratify patients with cytologically indeterminate thyroid nodules. Recently, a revision in the nomenclature of noninvasive thyroid nodules exhibiting a follicular architecture and papillary carcinoma-like nuclear features has resulted in a change from a malignant diagnosis (FVPTC) to one that is nonmalignant (NIFTP). It is interesting to note that the NIFTP diagnosis was not considered in the initial validation of the GEC test. 11 The main purpose of the current study was to evaluate the performance of GEC and its potential impact on clinical management in light of the revised nomenclature.
In the current study, we reported our experience with GEC in a tertiary institution, representing to the best of our knowledge the largest retrospective series of indeterminate thyroid nodules undergoing GEC testing and histopathologic confirmation published to date. As summarized in Table 4 , the results of the current study are consistent with the initial prospective validation study 11 and other retrospective follow-up studies, [24] [25] [26] [27] [28] [29] demonstrating that GEC has a high NPV of malignancy in indeterminate thyroid nodules. The pooled performance analysis highlighted an NPV of 97% in the AUS group and 90% in the SFN group. In effect, an indeterminate thyroid nodule with a benign GEC result is highly likely to be benign on confirmatory histopathology when surgically removed. Based on the current study results, approximately 46% of AUS nodules and 35% of SFN nodules would be classified as benign on GEC and therefore these patients would be exempted from unnecessary surgery. The main limitation of the current study, similar to other retrospective studies of GEC, is the relatively small number of histopathologic follow-up for nodules found to be benign on GEC. This potentially may bias the number of false-negative cases and it is impossible to assess true sensitivity, specificity, and NPV in this situation. Future studies with a prolonged follow-up period of GEC-benign nodules are necessary for the true performance of this test. Hurthle cell neoplasm presents another issue in the SFN category. Similar to the other studies, [24] [25] [26] [28] [29] [30] given that a significant number of benign Hurthle cell neoplasms would be classified as suspicious on GEC, the percentage of SFN nodules benefiting from GEC is less than AUS nodules. Cases diagnosed as SFN with Hurthle cell features are not recommended for GEC testing due to its low specificity. Separating lesions with and without Hurthle cell features in the SFN category may be helpful to maximize the benefit of GEC in the latter group. The introduction of NIFTP is expected to have a dramatic impact on the diagnosis and management of thyroid nodules. Recent studies have shown that although a preoperative FNA diagnosis of NIFTP can be distributed in any of the 6 Bethesda System for Reporting Thyroid Cytopathology categories, the majority of them would be classified as indeterminate. [31] [32] [33] [34] Therefore, the majority of patients with NIFTP may receive ancillary molecular testing under current recommended practice guidelines. 35 The issue of NIFTP and GEC was addressed in few recent studies, but to the best of our knowledge none of them provided detailed results for further pooled analysis.
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Wong et al reported a series of 63 indeterminate thyroid nodules measuring >1 cm with a suspicious GEC result.
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Of these cases, 61 were excised and 22 (35%) were malignant. Of the 16 tumors that originally were diagnosed as FVPTC, 14 were reclassified as noninvasive FVPTC, representing 64% of the malignant diagnoses. Samulski et al reported 288 cases of indeterminate thyroid nodules with available GEC results. 22 A total of 133 of these 288 cases (46%) were classified as suspicious by GEC. A total of 128 patients underwent diagnostic surgery and 44 nodules (34%) were malignant. Thirty-two tumors originally were diagnosed as FVPTC and 11 were reclassified as NIFTP, accounting for 24% of the malignant cases. Of the 11 NIFTP cases, only 1 case was classified as benign by GEC. Summarizing the experience with GEC and NIFTP, including the current study, a significant percentage of malignant tumors in indeterminate nodules found to be suspicious on GEC would be reclassified as NIFTP and thus nonmalignant. In the current analysis, this result impacts the PPV of malignancy in the GEC test, which significantly decreases from 42% to 24% in the AUS group and from 23% to 13% in the SFN group. These values are close to the rate of malignancy of an indeterminate FNA result before the introduction of NIFTP and molecular testing. 11, 36, 37 In this sense, the surgical procedure should not be performed based solely on a suspicious GEC result. Other factors such as the size of the nodules and ultrasonographic findings may further facilitate clinical decision making for an indeterminate nodule found to be suspicious on GEC. 35, 38 Although this likely is biased by the limited number of patients with GEC-benign nodules undergoing diagnostic surgery, to our knowledge only 1 NIFTP case in the literature to date has been classified as benign by GEC. 22 Based on the conclusions of the 2012 validation study, the primary usefulness of GEC is to identify a subpopulation of patients with a low likelihood of malignancy when the result is benign. 11 However, in our institutional analysis of the impact of a suspicious GEC result on the surgical procedure, after excluding cases with bilateral nodules at the time of initial presentation, we demonstrated that total thyroidectomy was performed significantly more frequently than partial thyroidectomy within the past 4 years compared with pre-GEC AUS controls. This trend might be due to incorrectly equating a "suspicious" GEC result with a "suspicious" FNA diagnosis, which has a totally different clinical meaning. An FNA diagnosis of suspicious for malignancy has a rate of malignancy of 46% to 90% after excluding NIFTP, [32] [33] [34] which still justifies more aggressive treatment. Conversely, the PPV of a "suspicious" GEC result in indeterminate thyroid nodules is much lower, especially when NIFTP has been considered in the analysis. The results of the current study suggest possible overtreatment in AUS nodules with a suspicious GEC result, and less so for SFN nodules. Total thyroidectomy leads to postoperative hypothyroidism; lifelong thyroid hormone replacement therapy; and increased risks of hypocalcemia, temporary or permanent injury to the recurrent laryngeal nerve, and hematoma compared with partial thyroidectomy. 39 These issues need to be fully considered and discussed before proceeding to diagnostic surgery. In the pooled analysis, we demonstrate a relatively high rate of neoplasia in indeterminate thyroid nodules with a suspicious GEC result (69% in the pooled AUS group and 79% in the pooled SFN group). Given that essentially all follicular neoplasms still may require diagnostic surgery to exclude invasion, the rate of neoplasia may reflect the actual percentage of cases requiring surgical management in indeterminate nodules. The appropriateness of lobectomy for tumors measuring <4 cm is consistent with the current clinical practice guidelines. 35 The results of the current study report what to the best of our knowledge is the largest retrospective series of patients with indeterminate thyroid nodules receiving GEC testing and diagnostic surgery. We observed that after the introduction of NIFTP, the PPV of malignancy in GEC significantly decreased in both the AUS and SFN groups. Given a relatively low risk of malignancy, a suspicious GEC result should not immediately prompt surgery. Other factors, such as the size of the nodule, ultrasonographic findings, and the presence of contralateral disease also should be taken into consideration. Because the NPV of the GEC test remains excellent in indeterminate thyroid nodules, it is reasonable to follow patients with a benign GEC result without surgical intervention.
FUNDING SUPPORT
No specific funding was disclosed.
